<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02314923</url>
  </required_header>
  <id_info>
    <org_study_id>V920-004</org_study_id>
    <secondary_id>NLG0507</secondary_id>
    <secondary_id>V920-004</secondary_id>
    <nct_id>NCT02314923</nct_id>
  </id_info>
  <brief_title>Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)</brief_title>
  <official_title>A Phase 1 Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioProtection Systems Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ebola virus has infected and killed people, mostly in Africa. In 2014, the Ebola virus has
      affected several thousand people. There is no approved effective way to treat or prevent
      Ebola. Researchers are trying to develop a vaccine for it. This is a study of the anti-Ebola
      vaccine BPSC-1001 to see if it is safe and to see how it affects people's immune system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Between 1994 and the present, there have been many Ebola viruses (EBOV) outbreaks affecting
      mostly central Africa. However, the 2014 West African outbreak significantly exceeds all
      previous outbreaks in geographic range, number of individuals affected and in disruption of
      typical activities of civil society.

      This is a Phase 1 safety and tolerability study to evaluate a novel vaccine to Ebola using a
      live replicating vesicular stomatitis virus (VSV) replacing the gene encoding the G envelope
      glycoprotein with the gene encoding the envelope glycoprotein from the Zaire strain of Ebola
      (VSVΔG-ZEBOV also known as V920 and BPSC-1001).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 5, 2014</start_date>
  <completion_date type="Actual">June 23, 2016</completion_date>
  <primary_completion_date type="Actual">June 23, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study comprised two separate cohorts. Cohort 1 consisted of the 4 lower V920 dose groups (3x10^3 pfu, 3x10^4 pfu, 3x10^5 pfu, and 3x10^6 pfu). Cohort 2 consisted of the 3 higher V920 dose groups (9x10^6 pfu, 2x10^7 pfu, 1x10^8 pfu) plus a bridging group that received vaccine at the highest dose evaluated in Cohort 1 (i.e. 3x10^6 pfu). Both Cohorts 1 and 2 had a placebo group.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity</measure>
    <time_frame>Up to 14 days postvaccination</time_frame>
    <description>An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, tenderness and swelling. AEs were assessed for severity by the investigator according to a toxicity grading scale based on the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least 1 solicited injection-site AE was summarized by grade.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity</measure>
    <time_frame>Up to 14 days postvaccination</time_frame>
    <description>An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Systemic AEs included subjective and objective fever, shivering/chills, sweats, myalgia, arthralgia, joint swelling, joint tenderness, fatigue, headache, gastrointestinal symptoms (nausea, vomiting, abdominal pain, and diarrhea), mucosal lesion, and skin lesion (including any blisters). AEs were assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least one systemic AE was summarized by grade.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity</measure>
    <time_frame>Up to 56 days postvaccination</time_frame>
    <description>An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Unsolicited vaccine-related AEs were those events not specifically listed as either an injection-site (local) or systemic in the VRC and were reported as at least possibly related to the study vaccine or placebo. The AEs were further assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least one unsolicited vaccine-related AE was summarized by grade..</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity</measure>
    <time_frame>Up to 360 days postvaccination</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An SAE is an AE that results in death, is life-threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event. SAEs were assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening; 5=Fatal. The percentage of participants that experienced at least 1 SAE was summarized by grade.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody</measure>
    <time_frame>28 days postvaccination</time_frame>
    <description>Blood was drawn on Day 28 to assess the GMTs of ZEBOV-specific IgG antibodies as determined by Enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimum Dose for General Use Prophylaxis With V920</measure>
    <time_frame>Day 360</time_frame>
    <description>The optimum dose for general use prophylaxis with V920 was determined following the review of all immunogenicity and safety data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ)</measure>
    <time_frame>Days 1, 2, 3, 4, 7, 14 and 28 post-vaccination</time_frame>
    <description>Participants had blood, assessed for evidence of V920 via polymerase chain reaction (PCR). Mean copies of RNA was reported for all participants who had reading ≥ the LLOQ (62.5 copies/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion for ZEBOV-specific IgG</measure>
    <time_frame>7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days postvaccination</time_frame>
    <description>Blood was drawn on Days 7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days to assess the GMTs via ELISA. Seroconversion was defined as a post-vaccination titer ≥ 200 ELISA Units/mL that was also at least a 4-fold increase in titer compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies</measure>
    <time_frame>7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days postvaccination</time_frame>
    <description>Blood was drawn on Days 7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days to assess the GMTs of Zaire ebolavirus neutralizing antibodies as determined plaque reduction neutralization titer (reciprocal of the dilution that resulted in a 60% decrease in plaques) (PRNT60).</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">513</enrollment>
  <condition>Ebola Virus</condition>
  <arm_group>
    <arm_group_label>3x10^3 pfu Vaccine Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 1-mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3x10^4 pfu Vaccine Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 1-mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3x10^5 pfu Vaccine Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 1-mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3x10^6 pfu Vaccine Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9x10^6 pfu Vaccine Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 1-mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2x10^7 pfu Vaccine Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1x10^8 pfu Vaccine Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3x10^6 pfu Vaccine Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 1-mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V920 Vaccine</intervention_name>
    <description>Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^3, 3x10^4, 3x10^5, 3x10^6, 9x10^6, 2x10^7, or 1x10^8 pfu.</description>
    <arm_group_label>1x10^8 pfu Vaccine Cohort 2</arm_group_label>
    <arm_group_label>2x10^7 pfu Vaccine Cohort 2</arm_group_label>
    <arm_group_label>3x10^3 pfu Vaccine Cohort 1</arm_group_label>
    <arm_group_label>3x10^4 pfu Vaccine Cohort 1</arm_group_label>
    <arm_group_label>3x10^5 pfu Vaccine Cohort 1</arm_group_label>
    <arm_group_label>3x10^6 pfu Vaccine Cohort 1</arm_group_label>
    <arm_group_label>3x10^6 pfu Vaccine Cohort 2</arm_group_label>
    <arm_group_label>9x10^6 pfu Vaccine Cohort 2</arm_group_label>
    <other_name>BPSC-1001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Saline</description>
    <arm_group_label>Placebo Cohort 1</arm_group_label>
    <arm_group_label>Placebo Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult male or non-pregnant, non-lactating adult female, ages 18 to 60
             (inclusive) at the time of screening

          2. Have provided written informed consent prior to screening procedures

          3. Free of clinically significant health problems, as determined by pertinent medical
             history, physical examination and clinical judgment of the investigator.

          4. Available, able, and willing to participate for all study visits and procedures.

          5. Males and females who are willing to practice abstinence from sexual intercourse with
             the opposite sex, or willing to use effective methods of contraception, from at least
             30 days prior to vaccination until study end.

          6. Be willing to minimize blood and body fluid exposure of others for 7 days after
             vaccination by:

               1. Using effective barrier prophylaxis, such as latex condoms, during penetrative
                  sexual intercourse

               2. Avoiding the sharing of needles, razors, or toothbrushes

               3. Avoiding open-mouth kissing

          7. Resides in the geographic area of a clinical study site for 1 year after vaccination
             without risk of deployment outside the U.S.

        Exclusion Criteria:

          1. History of prior infection with a filovirus or prior participation in a filovirus
             vaccine trial

          2. History of prior infection with VSV or receipt of a VSV vectored vaccine

          3. Has been involved in the care in any capacity of a patient with Ebola virus infection
             within the previous 21 days

          4. Is a healthcare worker who has direct contact with patients (nurse, physician,
             dentist, emergency medical technician, dental hygienist)

          5. Has a house-hold contact (HHC) who is immunodeficient, on immunosuppressive
             medications, human immunodeficiency virus (HIV)-positive, pregnant, has an unstable
             medical condition

          6. Has an HHC, or is a childcare worker who has direct contact with children, 5 years of
             age or younger

          7. Direct hands-on job preparing food in the food industry

          8. History of employment in an industry involved in contact with ruminant animals,
             veterinary sciences, or other potential exposure to VSV

          9. History of employment or activity which involves potential contact with filoviruses

         10. History of severe local or systemic reactions to any vaccination or a history of
             severe allergic reactions

         11. Known allergy to the components of the BPSC1001 vaccine product

         12. Receipt of investigational product up to 30 days prior to randomization or ongoing
             participation in another clinical trial

         13. Receipt of licensed non-live vaccines within 14 days of planned study immunization (30
             days for live vaccines)

         14. Ability to observe possible local reactions at the eligible injections sites (deltoid
             region) is, in the opinion of the investigator, unacceptably obscured due to a
             physical condition or permanent body art

         15. Acute or chronic, clinically significant psychiatric, hematologic, pulmonary,
             cardiovascular, or hepatic or renal functional abnormality as determined by the
             investigator based on medical history, physical examination, and/or laboratory
             screening test. This would include a known hemoglobinopathy or coagulation
             abnormality.

         16. Any baseline laboratory screening test which in the opinion of the investigator, is
             considered clinically significant

         17. Any serologic evidence of hepatitis B or C infection

         18. Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             HIV-1, HIV-2 infection, cytotoxic therapy in the previous 5 years, and/or diabetes

         19. Any chronic or active neurologic disorder, including migraines, seizures, and
             epilepsy, excluding a single febrile seizure as a child

         20. Have a known history of Guillain-Barré Syndrome

         21. Have an active malignancy or history of metastatic or hematologic malignancy

         22. Suspected or known alcohol and/or illicit drug abuse within the past 5 years

         23. Moderate or severe illness and/or fever &gt;100.4°F within 1 week prior to vaccination
             (can be rescheduled)

         24. Pregnant or lactating female, or female who intends to become pregnant during the
             study period

         25. Administration of IgGs and/or any blood products within the 120 days preceding study
             entry or planned administration during the study period

         26. History of blood donation within 60 days of enrollment or plans to donate within the
             study period

         27. Administration of chronic (defined as more than 14 days) immunosuppressants or other
             immune modifying drugs within 6 months of study entry

               1. For corticosteroids, this includes prednisone, or equivalent, greater than or
                  equal to 0.5 mg/kg/day

               2. Intranasal, topical, and intra-articular steroids are allowed

         28. Unwilling to allow storage and use of blood for future vaccine research

        28. Research staff or the immediate family of research staff directly involved with the
        clinical study.

        29. Unwilling to undergo diagnostic evaluation of joint signs and symptoms, which may
        include arthrocentesis if clinically indicated based on presence of effusion and if the
        procedure is acceptable to the subject at the time (Cohort 2 only) 30. Unwilling to undergo
        diagnostic evaluation of skin rash, to include punch biopsy if clinically indicated and if
        the procedure is acceptable to the subject at the time (Cohort 2 only) 31. Research staff
        or the immediate family of research staff directly involved in the clinical study 32. Any
        other significant finding that in the opinion of the investigator would increase the risk
        of the individual having an adverse outcome from participating in this study 33. Elective
        surgery or hospitalization planned during the period of study participation 34. Has
        traveled to an area where the World Health Organization has declared as an Ebola outbreak
        zone 35. History of chronic inflammatory disease (e.g., rheumatoid arthritis, psoriatic
        arthritis, reactive arthritis, ankylosing spondylitis, systemic lupus erythematosus,
        psoriasis, Crohn's disease, ulcerative colitis, and gout), symptomatic osteoarthritis, or
        any other autoimmune or autoinflammatory disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Heppner DG Jr, Kemp TL, Martin BK, Ramsey WJ, Nichols R, Dasen EJ, Link CJ, Das R, Xu ZJ, Sheldon EA, Nowak TA, Monath TP; V920-004 study team. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017 Aug;17(8):854-866. doi: 10.1016/S1473-3099(17)30313-4. Epub 2017 Jun 9.</citation>
    <PMID>28606591</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 8, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <results_first_submitted>December 6, 2019</results_first_submitted>
  <results_first_submitted_qc>December 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2020</results_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>3x10^3 Plaque-forming Units (Pfu) V920: Cohort 1</title>
          <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="P2">
          <title>3x10^4 Pfu V920: Cohort 1</title>
          <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="P3">
          <title>3x10^5 Pfu V920: Cohort 1</title>
          <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="P4">
          <title>3x10^6 Pfu V920: Cohort 1</title>
          <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="P5">
          <title>Placebo: Cohort 1</title>
          <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0.</description>
        </group>
        <group group_id="P6">
          <title>3x10^6 Pfu V920: Cohort 2</title>
          <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0</description>
        </group>
        <group group_id="P7">
          <title>9x10^6 Pfu V920: Cohort 2</title>
          <description>Participants received a 1.0 mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="P8">
          <title>2x10^7 Pfu V920: Cohort 2</title>
          <description>Participants received a single 1.0 mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="P9">
          <title>1x10^8 Pfu V920: Cohort 2</title>
          <description>Participants received a single 1.0 mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="P10">
          <title>Placebo: Cohort 2</title>
          <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="74"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="48"/>
                <participants group_id="P8" count="47"/>
                <participants group_id="P9" count="48"/>
                <participants group_id="P10" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="74"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="47">One participant did not receive vaccination due to missing blood sample at randomization.</participants>
                <participants group_id="P8" count="47"/>
                <participants group_id="P9" count="48"/>
                <participants group_id="P10" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="73"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="43"/>
                <participants group_id="P8" count="42"/>
                <participants group_id="P9" count="46"/>
                <participants group_id="P10" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant unavailable</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant relocation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics were reported for treated participants. 1 participant in 9x10^6 pfu V920: Cohort 2 arm did not receive vaccine</population>
      <group_list>
        <group group_id="B1">
          <title>3x10^3 Pfu V920: Cohort 1</title>
          <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0</description>
        </group>
        <group group_id="B2">
          <title>3x10^4 Pfu V920: Cohort 1</title>
          <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="B3">
          <title>3x10^5 Pfu V920: Cohort 1</title>
          <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="B4">
          <title>3x10^6 Pfu V920: Cohort 1</title>
          <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="B5">
          <title>Placebo Cohort 1</title>
          <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0.</description>
        </group>
        <group group_id="B6">
          <title>3x10^6 Pfu V920: Cohort 2</title>
          <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0</description>
        </group>
        <group group_id="B7">
          <title>9x10^6 Pfu V920: Cohort 2</title>
          <description>Participants received a 1.0 mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="B8">
          <title>2x10^7 Pfu V920: Cohort 2</title>
          <description>Participants received a 1.0 mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="B9">
          <title>1x10^8 Pfu V920: Cohort 2</title>
          <description>Participants received a 1.0 mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="B10">
          <title>Placebo: Cohort 2</title>
          <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="64"/>
            <count group_id="B4" value="64"/>
            <count group_id="B5" value="74"/>
            <count group_id="B6" value="20"/>
            <count group_id="B7" value="47"/>
            <count group_id="B8" value="47"/>
            <count group_id="B9" value="48"/>
            <count group_id="B10" value="20"/>
            <count group_id="B11" value="512"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="74"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="47"/>
                    <measurement group_id="B8" value="47"/>
                    <measurement group_id="B9" value="48"/>
                    <measurement group_id="B10" value="20"/>
                    <measurement group_id="B11" value="512"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="15"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="245"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="33"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity</title>
        <description>An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, tenderness and swelling. AEs were assessed for severity by the investigator according to a toxicity grading scale based on the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least 1 solicited injection-site AE was summarized by grade.</description>
        <time_frame>Up to 14 days postvaccination</time_frame>
        <population>All randomized participants who received study vaccination and had data available for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>3x10^3 Pfu V920: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>3x10^4 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>3x10^5 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>3x10^6 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>3x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0</description>
          </group>
          <group group_id="O7">
            <title>9x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O8">
            <title>2x10^7 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O9">
            <title>1x10^8 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O10">
            <title>Placebo: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity</title>
          <description>An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, tenderness and swelling. AEs were assessed for severity by the investigator according to a toxicity grading scale based on the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least 1 solicited injection-site AE was summarized by grade.</description>
          <population>All randomized participants who received study vaccination and had data available for the endpoint.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="47"/>
                <count group_id="O9" value="48"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1 (Mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                    <measurement group_id="O2" value="21.9"/>
                    <measurement group_id="O3" value="29.7"/>
                    <measurement group_id="O4" value="45.3"/>
                    <measurement group_id="O5" value="10.8"/>
                    <measurement group_id="O6" value="30.0"/>
                    <measurement group_id="O7" value="61.7"/>
                    <measurement group_id="O8" value="63.8"/>
                    <measurement group_id="O9" value="47.9"/>
                    <measurement group_id="O10" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 (Moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="1.6"/>
                    <measurement group_id="O5" value="1.4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="8.5"/>
                    <measurement group_id="O8" value="8.5"/>
                    <measurement group_id="O9" value="16.7"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 (Severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 (Potentially life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity</title>
        <description>An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Systemic AEs included subjective and objective fever, shivering/chills, sweats, myalgia, arthralgia, joint swelling, joint tenderness, fatigue, headache, gastrointestinal symptoms (nausea, vomiting, abdominal pain, and diarrhea), mucosal lesion, and skin lesion (including any blisters). AEs were assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least one systemic AE was summarized by grade.</description>
        <time_frame>Up to 14 days postvaccination</time_frame>
        <population>All randomized participants who received study vaccination and had data available for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>3x10^3 Pfu V920: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>3x10^4 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>3x10^5 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>3x10^6 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>3x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0</description>
          </group>
          <group group_id="O7">
            <title>9x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O8">
            <title>2x10^7 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O9">
            <title>1x10^8 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O10">
            <title>Placebo: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity</title>
          <description>An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Systemic AEs included subjective and objective fever, shivering/chills, sweats, myalgia, arthralgia, joint swelling, joint tenderness, fatigue, headache, gastrointestinal symptoms (nausea, vomiting, abdominal pain, and diarrhea), mucosal lesion, and skin lesion (including any blisters). AEs were assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least one systemic AE was summarized by grade.</description>
          <population>All randomized participants who received study vaccination and had data available for the endpoint.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="47"/>
                <count group_id="O9" value="48"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1 (Mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7"/>
                    <measurement group_id="O2" value="39.1"/>
                    <measurement group_id="O3" value="45.3"/>
                    <measurement group_id="O4" value="53.1"/>
                    <measurement group_id="O5" value="41.9"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="46.8"/>
                    <measurement group_id="O8" value="46.8"/>
                    <measurement group_id="O9" value="43.8"/>
                    <measurement group_id="O10" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 (Moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="4.7"/>
                    <measurement group_id="O3" value="10.9"/>
                    <measurement group_id="O4" value="14.1"/>
                    <measurement group_id="O5" value="4.1"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="19.1"/>
                    <measurement group_id="O8" value="23.4"/>
                    <measurement group_id="O9" value="27.1"/>
                    <measurement group_id="O10" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 (Severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3.1"/>
                    <measurement group_id="O4" value="1.6"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2.1"/>
                    <measurement group_id="O8" value="4.3"/>
                    <measurement group_id="O9" value="4.2"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 (Potentially life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity</title>
        <description>An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Unsolicited vaccine-related AEs were those events not specifically listed as either an injection-site (local) or systemic in the VRC and were reported as at least possibly related to the study vaccine or placebo. The AEs were further assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least one unsolicited vaccine-related AE was summarized by grade..</description>
        <time_frame>Up to 56 days postvaccination</time_frame>
        <population>All randomized participants who received study vaccination and had data available for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>3x10^3 Pfu V920: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>3x10^4 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>3x10^5 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>3x10^6 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>3x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0</description>
          </group>
          <group group_id="O7">
            <title>9x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O8">
            <title>2x10^7 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O9">
            <title>1x10^8 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O10">
            <title>Placebo: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity</title>
          <description>An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Unsolicited vaccine-related AEs were those events not specifically listed as either an injection-site (local) or systemic in the VRC and were reported as at least possibly related to the study vaccine or placebo. The AEs were further assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least one unsolicited vaccine-related AE was summarized by grade..</description>
          <population>All randomized participants who received study vaccination and had data available for the endpoint.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="47"/>
                <count group_id="O9" value="48"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 (Mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="14.1"/>
                    <measurement group_id="O3" value="7.8"/>
                    <measurement group_id="O4" value="9.4"/>
                    <measurement group_id="O5" value="6.8"/>
                    <measurement group_id="O6" value="15.0"/>
                    <measurement group_id="O7" value="14.9"/>
                    <measurement group_id="O8" value="17.0"/>
                    <measurement group_id="O9" value="14.6"/>
                    <measurement group_id="O10" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 (Moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="6.4"/>
                    <measurement group_id="O8" value="2.1"/>
                    <measurement group_id="O9" value="2.1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 (Severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.6"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 (Potentially Life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity</title>
        <description>An adverse event is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An SAE is an AE that results in death, is life-threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event. SAEs were assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening; 5=Fatal. The percentage of participants that experienced at least 1 SAE was summarized by grade.</description>
        <time_frame>Up to 360 days postvaccination</time_frame>
        <population>All randomized participants who received study vaccination and had data available for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>3x10^3 Pfu V920: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>3x10^4 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>3x10^5 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>3x10^6 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>3x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0</description>
          </group>
          <group group_id="O7">
            <title>9x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O8">
            <title>2x10^7 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O9">
            <title>1x10^8 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O10">
            <title>Placebo: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity</title>
          <description>An adverse event is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An SAE is an AE that results in death, is life-threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event. SAEs were assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening; 5=Fatal. The percentage of participants that experienced at least 1 SAE was summarized by grade.</description>
          <population>All randomized participants who received study vaccination and had data available for the endpoint.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="47"/>
                <count group_id="O9" value="48"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 (Mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.6"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 (Moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 (Severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1.4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 (Potentially Life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 (Fatal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.6"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody</title>
        <description>Blood was drawn on Day 28 to assess the GMTs of ZEBOV-specific IgG antibodies as determined by Enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>28 days postvaccination</time_frame>
        <population>All participants who were vaccinated, had endpoint titer results on Days 0 (baseline) and 28 (relative Days 24-35), and who did not have any protocol violations that influenced interpretation of immunogenicity endpoints. A subset of 25 placebo recipients in Cohort 1 were prospectively identified for testing of immunogenicity endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>3x10^3 Pfu V920: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>3x10^4 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>3x10^5 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>3x10^6 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>3x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0</description>
          </group>
          <group group_id="O7">
            <title>9x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O8">
            <title>2x10^7 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O9">
            <title>1x10^8 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O10">
            <title>Placebo: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody</title>
          <description>Blood was drawn on Day 28 to assess the GMTs of ZEBOV-specific IgG antibodies as determined by Enzyme-linked immunosorbent assay (ELISA).</description>
          <population>All participants who were vaccinated, had endpoint titer results on Days 0 (baseline) and 28 (relative Days 24-35), and who did not have any protocol violations that influenced interpretation of immunogenicity endpoints. A subset of 25 placebo recipients in Cohort 1 were prospectively identified for testing of immunogenicity endpoints.</population>
          <units>ELISA Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="46"/>
                <count group_id="O9" value="45"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="777.8" spread="5.06"/>
                    <measurement group_id="O2" value="767.8" spread="3.96"/>
                    <measurement group_id="O3" value="909.6" spread="3.26"/>
                    <measurement group_id="O4" value="1139.9" spread="3.25"/>
                    <measurement group_id="O5" value="30.3" spread="1.00"/>
                    <measurement group_id="O6" value="1518.9" spread="3.20"/>
                    <measurement group_id="O7" value="977.4" spread="3.01"/>
                    <measurement group_id="O8" value="1542.8" spread="3.10"/>
                    <measurement group_id="O9" value="1930.3" spread="2.22"/>
                    <measurement group_id="O10" value="35.9" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.951</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.458</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.071</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.325</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.427</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.065</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.303</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.286</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.094</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.757</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.348</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.508</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.191</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.169</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.961</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.454</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.068</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.370</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ)</title>
        <description>Participants had blood, assessed for evidence of V920 via polymerase chain reaction (PCR). Mean copies of RNA was reported for all participants who had reading ≥ the LLOQ (62.5 copies/mL)</description>
        <time_frame>Days 1, 2, 3, 4, 7, 14 and 28 post-vaccination</time_frame>
        <population>All participants who were vaccinated, had endpoint titer results on Days 0 (baseline) and 28 (relative Days 24-35), and who did not have any protocol violations that influenced interpretation of immunogenicity endpoints. A subset of 25 placebo recipients in Cohort 1 were prospectively identified for testing of immunogenicity endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>3x10^3 Pfu V920: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>3x10^4 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>3x10^5 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>3x10^6 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>3x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0</description>
          </group>
          <group group_id="O7">
            <title>9x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O8">
            <title>2x10^7 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O9">
            <title>1x10^8 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O10">
            <title>Placebo: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ)</title>
          <description>Participants had blood, assessed for evidence of V920 via polymerase chain reaction (PCR). Mean copies of RNA was reported for all participants who had reading ≥ the LLOQ (62.5 copies/mL)</description>
          <population>All participants who were vaccinated, had endpoint titer results on Days 0 (baseline) and 28 (relative Days 24-35), and who did not have any protocol violations that influenced interpretation of immunogenicity endpoints. A subset of 25 placebo recipients in Cohort 1 were prospectively identified for testing of immunogenicity endpoints.</population>
          <units>copies/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="46"/>
                <count group_id="O9" value="45"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="9"/>
                    <count group_id="O9" value="27"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="118.04" spread="1.185"/>
                    <measurement group_id="O6" value="109.40" spread="NA">SD could not be calculated due to low n</measurement>
                    <measurement group_id="O7" value="144.72" spread="1.511"/>
                    <measurement group_id="O8" value="184.65" spread="1.893"/>
                    <measurement group_id="O9" value="304.45" spread="2.534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="9"/>
                    <count group_id="O9" value="13"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4107.00" spread="NA">SD could not be calculated due to low n</measurement>
                    <measurement group_id="O4" value="127.13" spread="1.511"/>
                    <measurement group_id="O6" value="109.40" spread="NA">SD could not be calculated due to low n</measurement>
                    <measurement group_id="O7" value="158.74" spread="1.901"/>
                    <measurement group_id="O8" value="172.24" spread="1.628"/>
                    <measurement group_id="O9" value="161.67" spread="1.644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12649.00" spread="NA">SD could not be calculated due to low n</measurement>
                    <measurement group_id="O2" value="109.40" spread="NA">SD could not be calculated due to low n</measurement>
                    <measurement group_id="O4" value="703.36" spread="25.106"/>
                    <measurement group_id="O8" value="109.40" spread="NA">SD could not be calculated due to low n</measurement>
                    <measurement group_id="O9" value="740.96" spread="8.199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23936.00" spread="NA">SD could not be calculated due to low n</measurement>
                    <measurement group_id="O2" value="109.40" spread="NA">SD could not be calculated due to low n</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="787.00" spread="NA">SD could not be calculated due to low n</measurement>
                    <measurement group_id="O3" value="160.00" spread="NA">SD could not be calculated due to low n</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="109.40" spread="NA">SD could not be calculated due to low n</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion for ZEBOV-specific IgG</title>
        <description>Blood was drawn on Days 7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days to assess the GMTs via ELISA. Seroconversion was defined as a post-vaccination titer ≥ 200 ELISA Units/mL that was also at least a 4-fold increase in titer compared to baseline.</description>
        <time_frame>7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days postvaccination</time_frame>
        <population>All participants who were vaccinated, had endpoint titer results on Days 0 (baseline) and 28 (relative Days 24-35), and who did not have any protocol violations that influenced interpretation of immunogenicity endpoints. A subset of 25 placebo recipients in Cohort 1 were prospectively identified for testing of immunogenicity endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>3x10^3 Pfu V920: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>3x10^4 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>3x10^5 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>3x10^6 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>3x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0</description>
          </group>
          <group group_id="O7">
            <title>9x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O8">
            <title>2x10^7 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O9">
            <title>1x10^8 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O10">
            <title>Placebo: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion for ZEBOV-specific IgG</title>
          <description>Blood was drawn on Days 7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days to assess the GMTs via ELISA. Seroconversion was defined as a post-vaccination titer ≥ 200 ELISA Units/mL that was also at least a 4-fold increase in titer compared to baseline.</description>
          <population>All participants who were vaccinated, had endpoint titer results on Days 0 (baseline) and 28 (relative Days 24-35), and who did not have any protocol violations that influenced interpretation of immunogenicity endpoints. A subset of 25 placebo recipients in Cohort 1 were prospectively identified for testing of immunogenicity endpoints.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="46"/>
                <count group_id="O9" value="45"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="62"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2.2"/>
                    <measurement group_id="O9" value="2.2"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="62"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="44"/>
                    <count group_id="O9" value="44"/>
                    <count group_id="O10" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="20.3"/>
                    <measurement group_id="O3" value="20.6"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="40.0"/>
                    <measurement group_id="O7" value="54.5"/>
                    <measurement group_id="O8" value="81.8"/>
                    <measurement group_id="O9" value="72.7"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="63"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="45"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8"/>
                    <measurement group_id="O2" value="80.3"/>
                    <measurement group_id="O3" value="89.1"/>
                    <measurement group_id="O4" value="93.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="90.0"/>
                    <measurement group_id="O7" value="91.1"/>
                    <measurement group_id="O8" value="93.5"/>
                    <measurement group_id="O9" value="95.6"/>
                    <measurement group_id="O10" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="63"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="86.9"/>
                    <measurement group_id="O3" value="92.2"/>
                    <measurement group_id="O4" value="93.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="90.0"/>
                    <measurement group_id="O7" value="93.2"/>
                    <measurement group_id="O8" value="97.8"/>
                    <measurement group_id="O9" value="97.8"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7"/>
                    <measurement group_id="O2" value="85.2"/>
                    <measurement group_id="O3" value="87.3"/>
                    <measurement group_id="O4" value="93.4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="61"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="41"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="41"/>
                    <count group_id="O10" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0"/>
                    <measurement group_id="O2" value="75.9"/>
                    <measurement group_id="O3" value="83.6"/>
                    <measurement group_id="O4" value="89.9"/>
                    <measurement group_id="O6" value="94.4"/>
                    <measurement group_id="O7" value="90.2"/>
                    <measurement group_id="O8" value="97.6"/>
                    <measurement group_id="O9" value="97.6"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 360</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="57"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="38"/>
                    <count group_id="O8" value="39"/>
                    <count group_id="O9" value="41"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="80.4"/>
                    <measurement group_id="O4" value="89.5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="94.4"/>
                    <measurement group_id="O7" value="89.5"/>
                    <measurement group_id="O8" value="97.4"/>
                    <measurement group_id="O9" value="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any time postvaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="63"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="45"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1"/>
                    <measurement group_id="O2" value="90.2"/>
                    <measurement group_id="O3" value="93.8"/>
                    <measurement group_id="O4" value="96.8"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="100.0"/>
                    <measurement group_id="O7" value="97.8"/>
                    <measurement group_id="O8" value="97.8"/>
                    <measurement group_id="O9" value="97.8"/>
                    <measurement group_id="O10" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies</title>
        <description>Blood was drawn on Days 7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days to assess the GMTs of Zaire ebolavirus neutralizing antibodies as determined plaque reduction neutralization titer (reciprocal of the dilution that resulted in a 60% decrease in plaques) (PRNT60).</description>
        <time_frame>7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days postvaccination</time_frame>
        <population>All participants who were vaccinated, had endpoint titer results on Days 0 (baseline) and 28 (relative Days 24-35), and who did not have any protocol violations that influenced interpretation of immunogenicity endpoints. A subset of 25 placebo recipients in Cohort 1 were prospectively identified for testing of immunogenicity endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>3x10^3 Pfu V920: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>3x10^4 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>3x10^5 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>3x10^6 Pfu V920: Cohort 1</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Placebo: Cohort 1</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>3x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0</description>
          </group>
          <group group_id="O7">
            <title>9x10^6 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O8">
            <title>2x10^7 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O9">
            <title>1x10^8 Pfu V920: Cohort 2</title>
            <description>Participants received a 1.0 mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.</description>
          </group>
          <group group_id="O10">
            <title>Placebo: Cohort 2</title>
            <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies</title>
          <description>Blood was drawn on Days 7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days to assess the GMTs of Zaire ebolavirus neutralizing antibodies as determined plaque reduction neutralization titer (reciprocal of the dilution that resulted in a 60% decrease in plaques) (PRNT60).</description>
          <population>All participants who were vaccinated, had endpoint titer results on Days 0 (baseline) and 28 (relative Days 24-35), and who did not have any protocol violations that influenced interpretation of immunogenicity endpoints. A subset of 25 placebo recipients in Cohort 1 were prospectively identified for testing of immunogenicity endpoints.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="46"/>
                <count group_id="O9" value="45"/>
                <count group_id="O10" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="63"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="45"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="1.6"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2.2"/>
                    <measurement group_id="O8" value="2.2"/>
                    <measurement group_id="O9" value="2.2"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="63"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="45"/>
                    <count group_id="O8" value="45"/>
                    <count group_id="O9" value="44"/>
                    <count group_id="O10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="13.6"/>
                    <measurement group_id="O3" value="42.9"/>
                    <measurement group_id="O4" value="52.4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="45.0"/>
                    <measurement group_id="O7" value="55.6"/>
                    <measurement group_id="O8" value="71.1"/>
                    <measurement group_id="O9" value="81.8"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="63"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="45"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2"/>
                    <measurement group_id="O2" value="70.5"/>
                    <measurement group_id="O3" value="87.5"/>
                    <measurement group_id="O4" value="93.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="85.0"/>
                    <measurement group_id="O7" value="91.1"/>
                    <measurement group_id="O8" value="95.7"/>
                    <measurement group_id="O9" value="100.0"/>
                    <measurement group_id="O10" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="63"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.4"/>
                    <measurement group_id="O2" value="70.5"/>
                    <measurement group_id="O3" value="89.1"/>
                    <measurement group_id="O4" value="93.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="90.0"/>
                    <measurement group_id="O7" value="93.2"/>
                    <measurement group_id="O8" value="95.7"/>
                    <measurement group_id="O9" value="97.8"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (Cohort 1 only)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="62"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8"/>
                    <measurement group_id="O2" value="72.1"/>
                    <measurement group_id="O3" value="88.9"/>
                    <measurement group_id="O4" value="90.3"/>
                    <measurement group_id="O5" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="61"/>
                    <count group_id="O4" value="62"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="42"/>
                    <count group_id="O9" value="41"/>
                    <count group_id="O10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0"/>
                    <measurement group_id="O2" value="81.0"/>
                    <measurement group_id="O3" value="88.5"/>
                    <measurement group_id="O4" value="91.9"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="94.4"/>
                    <measurement group_id="O7" value="95.2"/>
                    <measurement group_id="O8" value="95.2"/>
                    <measurement group_id="O9" value="100.0"/>
                    <measurement group_id="O10" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 360</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="57"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="38"/>
                    <count group_id="O8" value="39"/>
                    <count group_id="O9" value="44"/>
                    <count group_id="O10" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4"/>
                    <measurement group_id="O2" value="78.8"/>
                    <measurement group_id="O3" value="82.1"/>
                    <measurement group_id="O4" value="93.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="94.4"/>
                    <measurement group_id="O7" value="84.6"/>
                    <measurement group_id="O8" value="97.5"/>
                    <measurement group_id="O9" value="100.0"/>
                    <measurement group_id="O10" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any time postvaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="63"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="45"/>
                    <count group_id="O8" value="46"/>
                    <count group_id="O9" value="45"/>
                    <count group_id="O10" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1"/>
                    <measurement group_id="O2" value="88.5"/>
                    <measurement group_id="O3" value="96.9"/>
                    <measurement group_id="O4" value="98.4"/>
                    <measurement group_id="O5" value="4.0"/>
                    <measurement group_id="O6" value="100.0"/>
                    <measurement group_id="O7" value="97.8"/>
                    <measurement group_id="O8" value="100.0"/>
                    <measurement group_id="O9" value="100.0"/>
                    <measurement group_id="O10" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Optimum Dose for General Use Prophylaxis With V920</title>
        <description>The optimum dose for general use prophylaxis with V920 was determined following the review of all immunogenicity and safety data.</description>
        <time_frame>Day 360</time_frame>
        <population>All participants who received study vaccine</population>
        <group_list>
          <group group_id="O1">
            <title>All Vaccinated Participants</title>
            <description>All participants that received study vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Optimum Dose for General Use Prophylaxis With V920</title>
          <description>The optimum dose for general use prophylaxis with V920 was determined following the review of all immunogenicity and safety data.</description>
          <population>All participants who received study vaccine</population>
          <units>pfu</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 360 days</time_frame>
      <desc>All participants that received study vaccination (V920 dose or placebo).</desc>
      <group_list>
        <group group_id="E1">
          <title>3x10^3 Pfu V920: Cohort 1</title>
          <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="E2">
          <title>3x10^4 Pfu V920: Cohort 1</title>
          <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="E3">
          <title>3x10^5 Pfu V920: Cohort 1</title>
          <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="E4">
          <title>3x10^6 Pfu V920: Cohort 1</title>
          <description>Participants received a 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="E5">
          <title>Placebo: Cohort 1</title>
          <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0.</description>
        </group>
        <group group_id="E6">
          <title>3x10^6 Pfu V920: Cohort 2</title>
          <description>Participants received a single 1.0 mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0</description>
        </group>
        <group group_id="E7">
          <title>9x10^6 Pfu V920: Cohort 2</title>
          <description>Participants received a 1.0 mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="E8">
          <title>2x10^7 Pfu V920: Cohort 2</title>
          <description>Participants received a single 1.0 mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="E9">
          <title>1x10^8 Pfu V920: Cohort 2</title>
          <description>Participants received a single 1.0 mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.</description>
        </group>
        <group group_id="E10">
          <title>Placebo: Cohort 2</title>
          <description>Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="43" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="41" subjects_at_risk="47"/>
                <counts group_id="E9" subjects_affected="41" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E8" events="7" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E9" events="13" subjects_affected="11" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E5" events="14" subjects_affected="12" subjects_at_risk="74"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E8" events="7" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E4" events="22" subjects_affected="21" subjects_at_risk="64"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E7" events="18" subjects_affected="16" subjects_at_risk="47"/>
                <counts group_id="E8" events="14" subjects_affected="13" subjects_at_risk="47"/>
                <counts group_id="E9" events="17" subjects_affected="15" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="64"/>
                <counts group_id="E4" events="24" subjects_affected="21" subjects_at_risk="64"/>
                <counts group_id="E5" events="16" subjects_affected="14" subjects_at_risk="74"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E7" events="22" subjects_affected="17" subjects_at_risk="47"/>
                <counts group_id="E8" events="25" subjects_affected="18" subjects_at_risk="47"/>
                <counts group_id="E9" events="25" subjects_affected="22" subjects_at_risk="48"/>
                <counts group_id="E10" events="6" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E4" events="19" subjects_affected="16" subjects_at_risk="64"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E6" events="8" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E7" events="18" subjects_affected="14" subjects_at_risk="47"/>
                <counts group_id="E8" events="24" subjects_affected="18" subjects_at_risk="47"/>
                <counts group_id="E9" events="20" subjects_affected="15" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="64"/>
                <counts group_id="E4" events="27" subjects_affected="26" subjects_at_risk="64"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E7" events="29" subjects_affected="28" subjects_at_risk="47"/>
                <counts group_id="E8" events="28" subjects_affected="28" subjects_at_risk="47"/>
                <counts group_id="E9" events="24" subjects_affected="24" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E10" events="4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E2" events="23" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E3" events="23" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E4" events="24" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E5" events="13" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E7" events="22" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E8" events="30" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E9" events="21" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E10" events="10" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E8" events="7" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="64"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E6" events="12" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E7" events="22" subjects_affected="19" subjects_at_risk="47"/>
                <counts group_id="E8" events="18" subjects_affected="16" subjects_at_risk="47"/>
                <counts group_id="E9" events="18" subjects_affected="16" subjects_at_risk="48"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E4" events="20" subjects_affected="20" subjects_at_risk="64"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E7" events="30" subjects_affected="28" subjects_at_risk="47"/>
                <counts group_id="E8" events="28" subjects_affected="27" subjects_at_risk="47"/>
                <counts group_id="E9" events="25" subjects_affected="25" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="24" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="64"/>
                <counts group_id="E3" events="27" subjects_affected="20" subjects_at_risk="64"/>
                <counts group_id="E4" events="41" subjects_affected="32" subjects_at_risk="64"/>
                <counts group_id="E5" events="33" subjects_affected="23" subjects_at_risk="74"/>
                <counts group_id="E6" events="12" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E7" events="32" subjects_affected="23" subjects_at_risk="47"/>
                <counts group_id="E8" events="30" subjects_affected="22" subjects_at_risk="47"/>
                <counts group_id="E9" events="28" subjects_affected="21" subjects_at_risk="48"/>
                <counts group_id="E10" events="11" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E8" events="12" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E9" events="15" subjects_affected="13" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E9" events="5" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All data may be published in the open medical literature with the identity of the subjects protected. Anyone desiring to publish or present data obtained during the conduct of the study will conform to the Sponsor’s policies and then forward the publication for review to the Sponsor prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

